SHENZHEN, Chine, 31 juillet 2024 /PRNewswire/ — Le 28 juillet 2024, Kexing Biopharm a annoncé l’approbation par la Commission européenne d’Apexelsin®, le médicament générique de l’Abraxane®(Nab-paclitaxel) de Bristol Myers Squibb et Celgene. Apexelsin® est développé par WhiteOak…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.